MarketCapExport financials
Edwards Lifesciences Corporation (EW)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Edwards Lifesciences Corporation Income Statement 2025-2007 | EW
Brief overview of income trends at Edwards Lifesciences Corporation
This overview is based on financial performance over the past five years. The revenue attributed to Edwards Lifesciences Corporation moved from $4.4 billion to $6.1 billion between the two endpoints. The cumulative result was +38.3%, corresponding to roughly 6.7% per year. Sales increased steadily, although without strong acceleration.
Gross profit was $3.3 billion at the start and $4.7 billion at the end of the period (+43.2%). The relationship between sales and direct costs improved over the period. Gross margin moved from 75.4% to 78%. Improving gross profitability strengthens the quality of revenue growth.
The five-year EBITDA result moved by +41.4%: from 1 billion dollars to 1.4 billion dollars. The operating result changed at a rate similar to sales. EBITDA margin moved from 22.9% to 23.4%. Operating efficiency did not change materially.
The five-year change in net income was +30.4%: from 823 million dollars to 1.1 billion dollars. Profit changed without establishing a distinct trend.
The market value of the business moved from 51.7 billion dollars to 48.8 billion dollars, or −5.6%. The market did not materially reprice the business.
Financial takeaway
The indicators form a favorable picture of business development. The positive side is supported by net-income growth, a larger revenue base and a steady EBITDA margin. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Edwards Lifesciences Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
48.8 B | 42.5 B | 53 B | 47.8 B | 70 B | 51.7 B | 48.7 B | 35.3 B | 26.7 B | 20.5 B | 16.9 B | 13.3 B | 7.31 B | 10.3 B | 8.97 B | 987 M | 614 M | 538 M | - |
Shares |
585 M | 598 M | 607 M | 619 M | 623 M | 623 M | 625 M | 628 M | 633 M | 639 M | 646 M | 639 M | 670 M | 689 M | 688 M | 114 M | 112 M | 112 M | - |
Historical Prices |
83.5 | 71.1 | 87.3 | 77.2 | 112 | 83.1 | 68.3 | 56.4 | 44.6 | 31.3 | 29 | 22.2 | 11.6 | 14.3 | 12.2 | 8.68 | 5.46 | 4.82 | 4.2 |
Net Income |
1.07 B | 4.17 B | 1.4 B | 1.52 B | 1.5 B | 823 M | 1.05 B | 722 M | 584 M | 570 M | 495 M | 811 M | 392 M | 293 M | 237 M | 64.8 M | 47.6 M | 129 M | - |
Revenue |
6.07 B | 5.44 B | 5.01 B | 4.46 B | 5.23 B | 4.39 B | 4.35 B | 3.72 B | 3.44 B | 2.96 B | 2.49 B | 2.32 B | 2.05 B | 1.9 B | 1.68 B | - | - | - | - |
Cost of Revenue |
1.33 B | 1.12 B | 978 M | 724 M | 1.25 B | 1.08 B | 1.11 B | 939 M | 875 M | 797 M | 617 M | 626 M | 517 M | 491 M | 490 M | 408 M | 399 M | 420 M | - |
Gross Profit |
4.73 B | 4.32 B | 4.03 B | 3.74 B | 3.98 B | 3.31 B | 3.23 B | 2.78 B | 2.56 B | 2.17 B | 1.88 B | 1.7 B | 1.52 B | 1.4 B | 1.19 B | 1.04 B | 922 M | 818 M | - |
Operating Income |
1.26 B | 1.38 B | 1.31 B | 1.5 B | 1.69 B | 898 M | 1.15 B | 748 M | 1.09 B | 751 M | - | - | - | - | - | - | - | - | - |
Interest Expense |
7.2 M | 68.9 M | 17.6 M | 19.2 M | 18.4 M | 15.8 M | 20.7 M | 29.9 M | 23.2 M | 19.2 M | 17.2 M | 17.2 M | 9.8 M | 4.4 M | 3.1 M | 2.4 M | 2.7 M | 7.2 M | - |
EBITDA |
1.42 B | 1.53 B | 1.45 B | 1.64 B | 1.83 B | 1 B | 1.33 B | 1.15 B | 1.1 B | 855 M | 708 M | 551 M | 523 M | 466 M | 358 M | 56.5 M | 58.7 M | 55.6 M | - |
Operating Expenses |
- | - | - | - | - | - | 1.99 B | 1.71 B | 1.54 B | 1.38 B | 1.23 B | 1.21 B | 1.07 B | 997 M | 889 M | - | - | - | - |
General and Administrative Expenses |
2.09 B | 1.79 B | 1.58 B | 1.36 B | 1.49 B | 1.23 B | 1.24 B | 1.09 B | 985 M | 905 M | 851 M | 858 M | 746 M | 705 M | 642 M | 550 M | 509 M | 481 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Edwards Lifesciences Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
576 M | 579 M | 585 M | 587 M | 587 M | 589 M | 597 M | 602 M | 602 M | 601 M | 607 M | 607 M | 608 M | 608 M | 620 M | 621 M | 622 M | 624 M | 624 M | 622 M | 623 M | 624 M | 622 M | 620 M | 625 M | 209 M | 625 M | 624 M | 208 M | 208 M | 209 M | 210 M | 210 M | 210 M | 211 M | 210 M | 211 M | 212 M | 213 M | 212 M | 213 M | 215 M | 215 M | 215 M | 216 M | 108 M | 106 M | 106 M | 107 M | 109 M | 111 M | 113 M | 114 M | 114 M | 116 M | 115 M | 114 M | 114 M | 115 M | 115 M | 115 M | 114 M | 113 M |
Net Income |
242 M | 381 M | 291 M | 333 M | 358 M | - | 3.07 B | 366 M | 352 M | - | 385 M | 307 M | 340 M | - | 344 M | 406 M | 374 M | - | 340 M | 490 M | 338 M | 310 M | 325 M | -122 M | 311 M | 280 M | 275 M | 242 M | 250 M | 7 M | 226 M | 283 M | 207 M | -2.8 M | 170 M | 186 M | 230 M | 158 M | 141 M | 127 M | 143 M | 141 M | 118 M | 113 M | 123 M | 109 M | 94.6 M | 547 M | 60.3 M | 75.1 M | 76.8 M | 93.3 M | 144 M | 91.1 M | 69.2 M | 67.8 M | 65.1 M | 63.1 M | 51.6 M | 58.1 M | 63.9 M | 48 M | 57.5 M |
Revenue |
1.74 B | 1.65 B | 1.55 B | 1.53 B | 1.41 B | - | 1.35 B | 1.37 B | 1.33 B | - | 1.24 B | 1.3 B | 1.46 B | - | 1.32 B | 1.37 B | 1.34 B | - | 1.31 B | 1.38 B | 1.22 B | 1.19 B | 1.14 B | 925 M | 1.13 B | 1.17 B | 1.09 B | 1.09 B | 993 M | 978 M | 907 M | 944 M | 895 M | 888 M | 822 M | 842 M | 884 M | 768 M | 739 M | 759 M | 697 M | 671 M | 616 M | 617 M | 590 M | 618 M | 607 M | 575 M | 522 M | 536 M | 496 M | 517 M | 497 M | 510 M | 448 M | 482 M | 459 M | 430 M | 413 M | 431 M | 404 M | - | - |
Cost of Revenue |
392 M | 363 M | 345 M | 344 M | 302 M | - | 263 M | 276 M | 287 M | - | 251 M | 257 M | 330 M | - | 254 M | 269 M | 299 M | - | 312 M | 334 M | 293 M | - | 281 M | 238 M | 265 M | - | 292 M | 304 M | 232 M | - | 225 M | 246 M | 234 M | - | 213 M | 211 M | 216 M | - | 201 M | 202 M | 180 M | - | 147 M | 159 M | 136 M | - | 168 M | 151 M | 146 M | - | 128 M | 124 M | 121 M | - | 112 M | 130 M | 127 M | - | 126 M | 128 M | 117 M | 95.8 M | 100 M |
Gross Profit |
1.35 B | 1.29 B | 1.21 B | 1.19 B | 1.11 B | - | 1.09 B | 1.09 B | 1.04 B | - | 993 M | 1.04 B | 1.13 B | - | 1.07 B | 1.1 B | 1.04 B | - | 998 M | 1.04 B | 923 M | 895 M | 860 M | 687 M | 864 M | 888 M | 802 M | 783 M | 761 M | 743 M | 682 M | 698 M | 661 M | 653 M | 608 M | 631 M | 668 M | 554 M | 538 M | 557 M | 517 M | 495 M | 469 M | 458 M | 454 M | 458 M | 439 M | 424 M | 376 M | 392 M | 367 M | 394 M | 376 M | 385 M | 336 M | 352 M | 332 M | 311 M | 287 M | 303 M | 288 M | 253 M | 265 M |
Operating Income |
513 M | 478 M | 307 M | 411 M | 395 M | - | 351 M | 366 M | 349 M | - | 366 M | 264 M | 388 M | - | 402 M | 460 M | 439 M | - | 390 M | 542 M | 384 M | - | 358 M | -170 M | 358 M | - | 294 M | 268 M | 274 M | - | 249 M | 252 M | 252 M | - | 214 M | 241 M | 298 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
16.6 M | 71.5 M | 2.7 M | -1.3 M | 2.6 M | - | 27.9 M | 2 M | 5.7 M | - | 6.6 M | 2.5 M | 1.6 M | - | -2 M | 4.3 M | -3.3 M | - | 1.4 M | 4.4 M | 5.5 M | - | 5.7 M | -300 K | 1.9 M | - | 4.6 M | 1.4 M | 1.8 M | - | 300 K | - | 3.1 M | - | 100 K | 1.4 M | 2.4 M | - | 2.1 M | 2.4 M | 2.4 M | - | -200 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
597 M | 518 M | - | - | 431 M | - | - | - | 388 M | - | - | - | 424 M | - | 507 M | 460 M | 474 M | - | 492 M | 542 M | 416 M | - | 432 M | -121 M | 383 M | - | 360 M | 310 M | 295 M | - | 306 M | 290 M | 272 M | - | 275 M | 281 M | 319 M | - | 52.1 M | 33.9 M | 15.9 M | - | 51.3 M | 32.8 M | 16 M | - | 50.3 M | 32.3 M | 16.2 M | - | 45.8 M | 28.8 M | 14.1 M | - | 42.2 M | 27.8 M | 13.8 M | - | 43.2 M | 29.3 M | 14.5 M | 41.1 M | 27.7 M |
General and Administrative Expenses |
561 M | 522 M | 515 M | 502 M | 466 M | - | 421 M | 448 M | 428 M | - | 382 M | 410 M | 436 M | - | 377 M | 409 M | 370 M | - | 364 M | 374 M | 331 M | - | 307 M | 275 M | 308 M | - | 306 M | 308 M | 280 M | - | 270 M | 275 M | 256 M | - | 245 M | 244 M | 230 M | - | 230 M | 229 M | 213 M | - | 212 M | 214 M | 202 M | - | 222 M | 216 M | 197 M | - | 178 M | 187 M | 182 M | - | 168 M | 182 M | 177 M | - | 166 M | 163 M | 150 M | 133 M | 141 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Edwards Lifesciences Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Curacao
USA
Costa-rica
Canada
Britain
Israel
